Literature DB >> 1707225

Sickle cell anemia with few painful crises is characterized by decreased red cell deformability and increased number of dense cells.

S K Ballas1.   

Abstract

The frequency and severity of the painful sickle cell crisis vary greatly among affected patients. Aside from a high level of Hb F(greater than 20%) there is no established parameter which may modulate the clinical severity of the disease. In this paper we describe two groups of adult patients with homozygous SS and present their characteristics. The division into these two groups was on the basis of relatively low RBC deformability (less than or equal to 37% of control) and high RBC deformability (greater than 65% of control) in the steady state. None of the patients had alpha-gene deletion and all had Hb F level less than 6.0%. Each patient was followed for a minimum of 3 years. The number of dense cells was quantitated by centrifugation on discontinuous Stractan gradient. RBC deformability index in isotonic medium (DI 290) was determined by ektacytometry and expressed as % of control. The patients with low RBC deformability had significantly less painful crises and more leg ulcers than those patients with high RBC deformability. The average number of dense cells was 22.2% and 9.8% of total circulating cells in the first and second group respectively. Moreover, the group with high red cell deformability had 33% mortality during the study period whereas no deaths occurred in the group with low RBC deformability. The data indicate that there is a subset of patients with SS who have relatively few painful crises despite low Hb F level. We wish to designate these by the acronym MIDDD syndrome: Mild disease as far as painful crises are concerned, increased number of Dense cells, and Decreased red cell Deformability. In addition these patients have high incidence of leg ulcers, have low incidence of urinary tract infection, and less mortality. Cellular factors seem to contribute to the incidence of painful crises.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1707225     DOI: 10.1002/ajh.2830360211

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  23 in total

1.  Laboratory and echocardiography markers in sickle cell patients with leg ulcers.

Authors:  Caterina P Minniti; James G Taylor; Mariana Hildesheim; Patricia O'Neal; Jonathan Wilson; Oswaldo Castro; Victor R Gordeuk; Gregory J Kato
Journal:  Am J Hematol       Date:  2011-05-31       Impact factor: 10.047

2.  Gardos pathway to sickle cell therapies?

Authors:  Clinton H Joiner
Journal:  Blood       Date:  2008-04-15       Impact factor: 22.113

3.  Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease.

Authors:  Gregory J Kato; Vicki McGowan; Roberto F Machado; Jane A Little; James Taylor; Claudia R Morris; James S Nichols; Xunde Wang; Mirjana Poljakovic; Sidney M Morris; Mark T Gladwin
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

Review 4.  Hydrodynamic mechanisms of cell and particle trapping in microfluidics.

Authors:  A Karimi; S Yazdi; A M Ardekani
Journal:  Biomicrofluidics       Date:  2013-04-05       Impact factor: 2.800

5.  Red blood cell endothelial nitric oxide synthase does not modulate red blood cell storage hemolysis.

Authors:  Tamir Kanias; Ling Wang; Ashley Lippert; Daniel B Kim-Shapiro; Mark T Gladwin
Journal:  Transfusion       Date:  2012-08-15       Impact factor: 3.157

6.  End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain.

Authors:  Ann T Farrell; Julie Panepinto; C Patrick Carroll; Deepika S Darbari; Ankit A Desai; Allison A King; Robert J Adams; Tabitha D Barber; Amanda M Brandow; Michael R DeBaun; Manus J Donahue; Kalpna Gupta; Jane S Hankins; Michelle Kameka; Fenella J Kirkham; Harvey Luksenburg; Shirley Miller; Patricia Ann Oneal; David C Rees; Rosanna Setse; Vivien A Sheehan; John Strouse; Cheryl L Stucky; Ellen M Werner; John C Wood; William T Zempsky
Journal:  Blood Adv       Date:  2019-12-10

7.  Lupus anticoagulant and leg ulcers in sickle cell anemia.

Authors:  Edeghonghon E Olayemi; Godwin N Bazuaye
Journal:  Indian J Dermatol       Date:  2009-07       Impact factor: 1.494

8.  Subclinical ischaemic episodes during the steady state of sickle cell anaemia.

Authors:  N O Akinola; S M Stevens; I M Franklin; G B Nash; J Stuart
Journal:  J Clin Pathol       Date:  1992-10       Impact factor: 3.411

9.  Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions.

Authors:  Gregory J Kato; Robert P Hebbel; Martin H Steinberg; Mark T Gladwin
Journal:  Am J Hematol       Date:  2009-09       Impact factor: 10.047

Review 10.  Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins.

Authors:  Dominik J Schaer; Paul W Buehler; Abdu I Alayash; John D Belcher; Gregory M Vercellotti
Journal:  Blood       Date:  2012-12-20       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.